Pharmacokinetic Differences Between Cobicistat and Ritonavir on Warfarin

Abstract

Get full access to this article

View all access options for this article.

References

Tseng

Hughes

Seet

Phillips

EJ.

Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51:1008-1022. doi:10.1177/1060028017717018

Yeh

Gaver

Patterson

et al . Lopinavir/ritonavir induces hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52-60. doi:10.1097/01.qai.0000219774.20174.64

Tseng

Luetkehoelter

Walmsley

SL.

Increase in internationalized normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. AIDS. 2017;31:175-179. doi:10.1097/QAD.0000000000001275

Good

Gomes

Fulco

PP.

An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. AIDS. 2015;29:985-986. doi:10.1097/QAD.0000000000000630

Niemi

Backman

Fromm

Neuvonen

Kivisto

KT.

Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 2003;42:819-850.

Horn

Hansten

Chan

LN.

Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680. doi:10.1345/aph.1H423